Literature DB >> 10676630

Differences in estrogen receptor alpha variant messenger RNAs between normal human breast tissue and primary breast carcinomas.

M A van Dijk1, A A Hart, L J van 't Veer.   

Abstract

We evaluated the differences in prevalence and functional activity of human estrogen receptor alpha (hER) variant mRNA between 21 normal breast tissues and 41 primary breast carcinomas using a functional assay in yeast for the hER First, we found that the presence of wild-type hER, relative to the total amount of hER, differs markedly (P < 0.0001) between normal breast tissue (median, 85% wild-type hER) and breast tumors (median, 74% wild-type hER). Second, the hER variants with altered function that are present in normal breast tissue are mainly one-exon deleted splicing variants (median, 100%), whereas in breast tumors only half of all variants lack just one single exon (median, 50%; P < 0.0001). Our results suggest that hER-dependent estrogen responsiveness of breast tissue may change during tumor outgrowth, indicating that specific hER variants may play a role in breast cancer development or progression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10676630

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

Review 1.  Tamoxifen resistance in breast cancer: elucidating mechanisms.

Authors:  L C Dorssers; S Van der Flier; A Brinkman; T van Agthoven; J Veldscholte; E M Berns; J G Klijn; L V Beex; J A Foekens
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Inhibition of Neu-induced mammary carcinogenesis in transgenic mice expressing ERΔ3, a dominant negative estrogen receptor α variant.

Authors:  Vicki L Davis; Firdos Shaikh; Katie M Gallagher; Michael Villegas; Sheri L Rea; J Mark Cline; Claude L Hughes
Journal:  Horm Cancer       Date:  2012-09-12       Impact factor: 3.869

3.  Estrogen receptor alpha is a novel marker expressed by follicular dendritic cells in lymph nodes and tumor-associated lymphoid infiltrates.

Authors:  Anna Sapino; Paola Cassoni; Enza Ferrero; Massimo Bongiovanni; Luisella Righi; Nicoletta Fortunati; Pellegrino Crafa; Roberto Chiarle; Gianni Bussolati
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

4.  Alternative splicing of NUMB, APP and VEGFA as the features of pancreatic ductal carcinoma.

Authors:  Kai-Lian Zheng; Tian-Lin He; Wei-Ping Ji; Hui Jiang; Ye Shen; Gang Li; Si-Bo Zhu; Bing-Lei Tong; Yi-Jie Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

Review 5.  Alternative splicing and the progesterone receptor in breast cancer.

Authors:  David M W Cork; Thomas W J Lennard; Alison J Tyson-Capper
Journal:  Breast Cancer Res       Date:  2008-05-30       Impact factor: 6.466

6.  Clinical Significance of HER-2 Splice Variants in Breast Cancer Progression and Drug Resistance.

Authors:  Claire Jackson; David Browell; Hannah Gautrey; Alison Tyson-Capper
Journal:  Int J Cell Biol       Date:  2013-07-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.